We provide you with 20 years of free, institutional-grade data for CAPR stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of CAPR. Explore the full financial landscape of CAPR stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$3,103,403
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Bergmann Anthony | Sale | -24,100 | $30.38 | $732,158 | 2026-06-29 |
| Bergmann Anthony | Derivatives Exercise | 24,100 | 2026-06-29 | ||
| Krasney Karen | Sale | -24,100 | $30.38 | $732,158 | 2026-06-29 |
| Krasney Karen | Derivatives Exercise | 24,100 | 2026-06-29 | ||
| Krasney Karen | Sale | -900 | $30 | $27,000 | 2026-06-24 |
| Krasney Karen | Derivatives Exercise | 900 | 2026-06-24 | ||
| Bergmann Anthony | Sale | -900 | $30 | $27,000 | 2026-06-24 |
| Bergmann Anthony | Derivatives Exercise | 900 | 2026-06-24 | ||
| Bergmann Anthony | Derivatives Exercise | 3,000 | 2026-05-19 | ||
| Litvack Frank | Derivatives Exercise | 3,937 | 2026-05-14 | ||
| Bergmann Anthony | Sale | -25,000 | $31.7 | $792,540 | 2026-05-04 |
| Bergmann Anthony | Derivatives Exercise | 25,000 | 2026-05-04 | ||
| Krasney Karen | Sale | -25,000 | $31.7 | $792,548 | 2026-05-04 |
| Krasney Karen | Derivatives Exercise | 25,000 | 2026-05-04 | ||
| Sabar Karimah Es | Sale | -7,529 | $32 | $240,928 | 2026-04-03 |
| Sabar Karimah Es | Derivatives Exercise | 7,529 | 2026-04-03 | ||
| Krasney Karen | Sale | -25,000 | $30.12 | $752,935 | 2026-04-01 |
| Krasney Karen | Derivatives Exercise | 25,000 | 2026-04-01 | ||
| Sabar Karimah Es | Sale | -115,000 | $30.17 | $3,469,320 | 2026-04-01 |
| Sabar Karimah Es | Derivatives Exercise | 115,000 | 2026-04-01 | ||
| Bergmann Anthony | Sale | -25,000 | $30.13 | $753,153 | 2026-04-01 |
| Bergmann Anthony | Derivatives Exercise | 25,000 | 2026-04-01 | ||
| Krasney Karen | Derivatives Exercise | 2,500 | 2026-03-27 | ||
| DUNBAR GEORGE W JR | Derivatives Exercise | 3,000 | 2025-12-23 |
The information provided in this report about CAPR stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Capricor Therapeutics, Inc(NASDAQ:CAPR) 
Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has comp...
Website: http://www.capricor.com
Founded: 2005
Full Time Employees: 16
Sector: Healthcare
Industry: Biotechnology